None listed
Conditions
Interventions
Intervention1: Arsenicum Album: Dose - 30 C potency
Frequency -3 pill in the morning in a day.
Route of administration - Oral Duration of therapy - 3 days
Dose - 200 C potency
Frequency -3 pill i
Sponsors
School of Public Health SRMIST
Eligibility
Inclusion criteria
Inclusion criteria: Participants who are capable of giving signed informed consent. 6 months and older individuals in the study area, The participant is in good health in the opinion of the investigator as determined by a medical and psychiatric history. The participant must be willing and able to comply with study restrictions, to remain at the study area for the required duration during the study period and be available for the follow-up evaluations, as specified in this protocol.
Exclusion criteria
Exclusion criteria: COVID-19 positive as determined by RT-PCR, or other approved commercial or public health assay. Children less than 6 months Severe chronic kidney disease or cardiovascular diseases, cancer, AIDS or other life-threatening diseases. Immunocompromised patients taking (presently or anytime during last 90 days) immunosuppressant medication The person has participated in a clinical study of a new chemical entity or a prescription medicine within 3 months before administration of the first dose of the IMP The patient cannot participate or successfully complete the study, in the opinion of their healthcare provider or the investigator for any of the following reasons mentally or legally incapacitated or unable to give consent for any reason o unable to be contacted in case of emergency The patient is an employee of the sponsorparticipating study center who is directly involved in the study or is the relative of such an employee The patient has a history of alcohol and/or drug abuse that in the investigatorâ??s opinion could interfere with the study evaluations or the patientâ??s safety has any other condition, which, in the opinion of the investigator makes the patient inappropriate for inclusion in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome A reduction in attack rate of Covid19 in the intervention arm were prophylaxis Arsenicum Album is administered compared to control arm.Timepoint: The recruitment will start from 12-12-2020 and the it will end on 12-01-2021. The surveillance will start from 20-12-2020 and end by 20-01-2021 | — |
Secondary
| Measure | Time frame |
|---|---|
| Reduction in number of intervention arm participants reporting severity of disease symptoms, hospitalisation,, pneumonia, adverse events and mortality compared to control arm.Timepoint: The recruitment will start from 12-12-2020 and the it will end on 12-01-2021. The surveillance will start from 20-12-2020 and end by 20-01-2021 | — |
Countries
India
Contacts
Public ContactProf Padma Venkat
School of Public Health SRMIST
Outcome results
None listed